Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New Total-Body PET scanner could revolutionize vasculitis diagnosis

NCT ID NCT07628075

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study will test a new type of PET/CT scanner, called Long-Axial Field-of-View (LAFOV), to see if it can provide clearer images of blood vessel inflammation in people with large vessel vasculitis (LVV). The scanner is more sensitive and can image the whole body faster, potentially allowing for lower radiation doses and better detection of disease activity. Researchers will compare scans from 18 participants (12 with LVV and 6 healthy volunteers) to develop a standardized imaging protocol for future use.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
18F-FDG (a radioactive sugar) and CT contrast dye
What this could lead to
If successful, this could lead to a standardized, more accurate imaging protocol for diagnosing and monitoring large vessel vasculitis, potentially reducing unnecessary treatments.
What could go wrong
This is a very small, early-phase study (18 participants) focused on optimizing the imaging technique, not testing a treatment. The new method may not prove clearly better than current scans.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 18 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Jan 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria LVV Patients: * ≥18 years of age * Newly diagnosed LVV (based on the 2022 American College of Rheumatology (ACR) and European Alliance of Associations for Rheumatology (EULAR) classification criteria or from a definite diagnosis of LVV on standard of care imaging) * WHO performance status 0-2 * The subject is able and willing to comply with study procedures and signed and dated informed consent is obtained * eGFR of ≥30 (mL/min/1.73m2) within 3 months of \[18F\]FDG injection in subjects who have a history of renal impairment, renal disease, renal transplant or diabetes Exclusion Criteria LVV Patients: * The subject is pregnant or lactating * Participants with claustrophobia or who are unable to comfortably tolerate the scanning procedure * History of allergy to iodinated contrast * Commencement of steroids \> 7 days prior to administration of the radiotracer * Poorly controlled diabetic with a blood glucose \>11mmol/L * Evidence of a significant medical condition or laboratory finding which, in the opinion of the Investigator, makes it undesirable for the patient to participate in the trial. Inclusion Criteria Healthy Volunteers: * Three subjects ≥18 years of age that are also \< 50 years old and three subjects ≥50 years of age * WHO performance status 0-2 * The subject is able and willing to comply with study procedures and signed and dated informed consent is obtained Exclusion Criteria Healthy Volunteers: * The subject is pregnant or lactating * Participants with claustrophobia or who are unable to comfortably tolerate the scanning procedure * Participants with any contra-indication to MRI * Known allergy to gadolinium-based contrast agents * History of smoking * History or current diagnosis of the following medical conditions: * Diabetes Mellitus * Chronic Kidney Disease * Atrial Fibrillation * Migraines * Rheumatoid Arthritis * Systemic Lupus Erythematosus (SLE) * Historic or current prescription of the following medications: * Any blood pressure medication * Any antipsychotic medication * Steroids * Weight of ≥75Kg (in order to keep the radiation dose \<10mSV for HV) * Evidence of any significant medical condition which, in the opinion of the Investigator, makes it undesirable for the HV to participate in the trial * Participants that have undergone any imaging investigation that exposes them to radiation within the previous 12 months

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Giant cell arteritis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Imperial College Healthcare NHS Trust

    London, Greater London, W2 1NY, United Kingdom

  • King's College London

    London, Greater London, SE1 7EH, United Kingdom

  • Royal Free London NHS Foundation Trust

    London, Greater London, NW3 2QG, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.